Mesothelioma Clinical Trial


These are the listed clinical trials as of 2/6/02.

For a more current listing of clinical trials, click here and select "mesothelioma" under the diagnosis. Leave all other fields blank and press the search button at the bottom of the Web page. A current clinical mesothelioma trials will be listed. Select the trials that you would like to know more about and click on display.

  • Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Patients With Unresectable Lung or Esophageal Cancer, or Malignant Pleural Mesothelioma (NCI-T99-0012, NCI-99-C-0129)

  • Phase I Study of Inhaled Doxorubicin in Patients With Advanced Solid Tumors Affecting the Lungs (NCI-00-C-0088)

  • Phase I Study of Intraperitoneal Interleukin-12 in Patients With Mullerian Carcinoma, Peritoneal Mesothelioma, or Gastrointestinal Carcinoma With Abdominal Carcinomatosis (NCI-T97-0034, MDA-ID-97027)

  • Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Patients With Advanced Malignancies That Express Mesothelin (NCI-01-C-0011, NEOPHARM-SS1PE-001, NEOPHARM-MS-CI-01)

  • Phase II Randomized Study of Gemcitabine and Cisplatin With or Without Bevacizumab in Patients With Malignant Mesothelioma (NCI-2710, UCCRC-11046A)

  • Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Stage IV Mesothelioma (BRI-MA-2)

  • Phase II Study of Capecitabine in Patients With Malignant Mesothelioma (CLB-39807)

  • Phase II Study of Ecteinascidin 743 in Patients With Unresectable Malignant Mesothelioma (NCI-G01-2026, MSKCC-01084, PMAR-ET-B-020-99)

  • Phase II Study of Gemcitabine and Epirubicin in Patients With Malignant Pleural Mesothelioma (NCCTG-N0021)

  • Phase II Study of Radiofrequency Ablation in Patients With Refractory or Advanced Pulmonary Malignancies (UCLA-990802401a, NCI-G01-2011)

  • Phase II Study of SU5416 in Patients With Unresectable Malignant Mesothelioma (NCI-44, UCCRC-NCI-44)

  • Phase II Study of Surgery, Intraperitoneal Chemotherapy, and Whole Abdominal Radiotherapy in Patients With Peritoneal Mesothelioma (CPMC-IRB-13799, CPMC-IRB-7723, NCI-G01-2015)

  • Phase II Study of ZD 1839 in Patients With Malignant Mesothelioma (CLB-30101)

  • Phase III Randomized Study of Doxorubicin With or Without P-30 Protein (Onconase) in Patients with Malignant Mesothelioma (ALFACELL-P30-302, NCI-V97-1273)